Survey highlights success criteria for EU drug approval applications
This article was originally published in Scrip
Those companies most likely to get a new drug approved by the European Medicines Agency (EMA) tend to be larger firms with more resources and more experience in drug development and approval applications, and which have made full use of the scientific advice offered by the agency.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.